Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Open access
Hassan, Raffit, Blumenschein, George R., Moore, Kathleen N., Santin, Alessandro D., Kindler, Hedy L., Nemunaitis, John J., Seward, Shelly M., Thomas, Anish, Kim, Stella K., Rajagopalan, Prabhu, Walter, Annette O., Laurent, Dirk, Childs, Barrett H., Sarapa, Nenad, Elbi, Cem, Bendell, Johanna C. · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody–drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known to express the tumor-differentiation antigen mesothelin. PATIENTS AND METHODS: This phase I, open-label, multicenter, dose-escalation and dose-expansion study of anetumab ravtansine enrolled 148 adult patients with multiple solid tumor types. Ten dose-escalation cohorts of patients with advanced or metastatic solid tumors (0.15-7.5 mg/kg) received anetumab ravtansine once every 3 weeks, and 6 expansion cohorts of patients with advanced, recurrent ovarian cancer or malignant mesothelioma received anetumab ravtansine at the maximum tolerated dose once every 3 weeks, 1.8 mg/kg once per week, and 2.2 mg/kg once per week. RESULTS: Forty-five patients were enrolled across the 10 dose-escalation cohorts. The maximum tolerated dose of anetumab ravtansine was 6.5 mg/kg once every 3 weeks or 2.2 mg/kg once per week. Thirty-two patients were enrolled in the 6.5 mg/kg once-every-3-weeks, 35 in the 1.8 mg/kg once-per-week, and 36 in the 2.2 mg/kg once-per-week expansion cohorts. The most common drug-related adverse events were fatigue, nausea, diarrhea, anorexia, vomiting, peripheral sensory neuropathy, and keratitis/keratopathy. There were no drug-related deaths. Anetumab ravtansine pharmacokinetics were dose proportional; the average half-life was 5.5 days. Among 148 patients with mesothelioma or ovarian, pancreatic, non–small-cell lung, and breast cancers, 1 had a complete response, 11 had partial responses, and 66 had stable disease. High levels of tumor mesothelin expression were detected in patients with clinical activity. CONCLUSION: Anetumab ravtansine exhibited a manageable safety and favorable pharmacokinetic profile with encouraging preliminary antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors. The results allowed for the determination of recommended doses, schedules, and patient populations for anetumab ravtansine in phase II studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.02085

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. 10.1073/pnas.93.1.136 · DOI · Paper page
  2. 10.1002/ijc.2910500308 · DOI · Paper page
  3. 10.1038/sj.bjc.6604964 · DOI · Paper page
  4. 10.1097/00000478-200302000-00002 · doi:10.1097/00000478-200302000-00002
  5. 10.1097/01.MP.0000056981.16578.C3 · DOI · Paper page
  6. 10.1158/0008-5472.CAN-14-0337 · DOI · Paper page
  7. 10.1200/JCO.2016.68.3672 · DOI · Paper page
  8. 10.1158/2159-8290.CD-15-0583 · DOI · Paper page
  9. 10.1186/1476-4598-5-50 · DOI · Paper page
  10. 10.1074/jbc.M312372200 · DOI · Paper page
  11. 10.1158/1078-0432.CCR-07-0869 · DOI · Paper page
  12. Hassan R, 2014, Cancer, 120, 3311, 10.1002/cncr.28875 · DOI · Paper page
  13. 10.1158/1078-0432.CCR-09-0062 · DOI · Paper page
  14. 10.1158/1535-7163.MCT-13-0926 · DOI · Paper page
  15. 10.3390/molecules22081281 · DOI · Paper page
  16. 10.1186/s13046-017-0667-1 · DOI · Paper page
  17. 10.1097/JTO.0b013e318208c83d · DOI
  18. 10.1016/j.ejca.2008.10.026 · DOI · Paper page
  19. 10.1200/JCO.2017.76.6394 · DOI · Paper page
  20. 10.1080/19420862.2016.1156829 · DOI · Paper page
  21. 10.1007/s10637-014-0151-0 · DOI
  22. 10.1200/JCO.2011.39.4403 · DOI · Paper page
  23. 10.1016/j.yrtph.2016.10.012 · DOI
  24. 10.1200/JCO.2011.39.6671 · DOI · Paper page
  25. 10.1016/j.jtho.2017.09.328 · DOI
  26. 10.1111/j.1600-0609.2007.00928.x · doi:10.1111/j.1600-0609.2007.00928.x

Cited by

See all 173

Metadata

Authors
Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Thomas, A., Kim, S. K., Rajagopalan, P., Walter, A. O., Laurent, D., Childs, B. H., Sarapa, N., Elbi, C., & Bendell, J. C.
Venue
Journal of Clinical Oncology
Published
2020-06-01
Volume
38
Issue
16
Pages
1824-1835
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3013332534
Cited by
173
References
0
FWCI
11.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.19.02085
The paper
Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Thomas, A., Kim, S. K., Rajagopalan, P., Walter, A. O., Laurent, D., Childs, B. H., Sarapa, N., Elbi, C., & Bendell, J. C. (2020). First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.02085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.